Information  X 
Enter a valid email address

Redx Pharma PLC Ord 1P (REDX)

Date Time Source Announcement
14 Feb 2019 7:00 am
RNS
Directorate Update
12 Feb 2019 7:00 am
RNS
New in vivo data on ROCK2
06 Feb 2019 11:25 am
RNS
Receipt of Outstanding Loan
31 Jan 2019 7:00 am
RNS
Deinove return rights to Redx Programme
23 Jan 2019 11:25 am
RNS
Results of Annual General Meeting
21 Jan 2019 7:00 am
RNS
RXC004 Trial Approval
10 Jan 2019 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
03 Jan 2019 7:00 am
RNS
Redx to present at 2019 Biotech Showcase event
28 Dec 2018 11:47 am
RNS
Publication of Annual Report and Accounts
30 Nov 2018 8:45 am
EQS
RedX Pharma (REDX): RXC006: First fibrosis development candidate
  7:00 am
RNS
First RXC006 data for treatment of fibrosis
27 Nov 2018 4:05 pm
EQS
Redx Pharma (REDX): Streamlined, focused and good value
19 Nov 2018 7:00 am
RNS
Preliminary Results for year ended 30 Sept 2018
  7:00 am
RNS
CFO Announcement
14 Nov 2018 7:00 am
RNS
Redx announces new drug development candidate
09 Nov 2018 9:50 am
EQS
Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease
05 Nov 2018 7:00 am
RNS
Preclinical data presented at cancer conference
31 Oct 2018 7:00 am
RNS
Notice of Results
29 Oct 2018 7:00 am
RNS
Redx notes election of Lisa Anson to UK BIA BOD
26 Oct 2018 7:00 am
RNS
Details from Redx ROCK2 inhibitor poster
22 Oct 2018 7:00 am
RNS
Redx ROCK2 inhibitors poster to be presented
02 Oct 2018 1:40 pm
EQS
Redx Pharma (REX): Strategy launch
06 Sep 2018 7:15 am
EQS
Redx Pharma (REDX): Back to the clinic
04 Sep 2018 7:00 am
RNS
Redx Pharma Announces Way Forward For RXC004
18 Jun 2018 7:15 am
EQS
Redx Pharma (REDX): 'Focus, Realism and Results' - Ian Ross, Chairman
04 Jun 2018 7:00 am
RNS
Directorate Update and Grant of Options
30 May 2018 7:00 am
RNS
Interim Results
15 May 2018 12:00 pm
EQS
Redx Pharma (REDX): Clinical and corporate update
25 Apr 2018 10:57 am
RNS
Share Purchase by Chairman
  9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
24 Apr 2018 7:00 am
RNS
Redx Appoints Senior AstraZeneca Executive as CEO
13 Apr 2018 8:19 am
RNS
Holding(s) in Company
12 Apr 2018 11:28 am
RNS
Holding(s) in Company
29 Mar 2018 7:00 am
RNS
RXC004 Clinical Trial Update
22 Mar 2018 7:00 am
RNS
Redx and Deinove sign option and licence agreement
15 Mar 2018 7:00 am
RNS
Poster Presentation at AACR Annual Meeting
06 Mar 2018 4:33 pm
RNS
Result of AGM
12 Feb 2018 10:23 am
RNS
Posting of Annual Accounts & AGM notice
06 Feb 2018 7:00 am
RNS
First Patient Dosed in Phase 1/2a Trial of RXC004
22 Jan 2018 7:00 am
RNS
Appointment of Chief Medical Officer
28 Dec 2017 11:28 am
RNS
Holding(s) in Company
27 Dec 2017 5:45 pm
RNS
Share Purchase by Directors
22 Dec 2017 7:00 am
RNS
Grant of Options
20 Dec 2017 7:00 am
RNS
Final Results for the Year Ended 30 September 2017
14 Dec 2017 3:56 pm
RNS
Holding(s) in Company
08 Dec 2017 5:04 pm
RNS
Holding(s) in Company
14 Nov 2017 11:30 am
RNS
Director/PDMR Shareholding
13 Nov 2017 7:15 am
RNS
Hardman Research: Streamlined and clean
06 Nov 2017 12:00 pm
RNS
Restoration - Restoration Redx Pharma plc
  7:00 am
RNS
Redx updates strategy and resumes shares trading
03 Nov 2017 10:00 am
RNS
Exit from Administration
27 Oct 2017 8:00 am
RNS
Update on Application to the High Court
13 Oct 2017 7:00 am
RNS
Update on Court Process
31 Aug 2017 9:00 am
RNS
Redx to present new scientific data at ESMO 2017
24 Aug 2017 9:42 am
RNS
Distribution to Unsecured Creditors
14 Aug 2017 10:05 am
RNS
Directorate Change
10 Aug 2017 8:00 am
RNS
Publication of Joint Administrators' Proposals
31 Jul 2017 7:00 am
RNS
Disposal of BTK inhibitor drug development program
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t